Cerapedics, Inc.

Cerapedics is a biopharmaceutical company specializing in peptide-enhanced bone graft materials for spinal fusion surgery. The company develops and markets bone growth accelerators (BGAs) designed to improve fusion rates and reduce time to fusion in orthopedic procedures, particularly in the lumbar and cervical spine. Their primary product portfolio includes PearlMatrix™ P-15 Peptide Enhanced Bone Graft, recently FDA-approved as the first bone growth accelerator indicated to accelerate fusion in lumbar spine (single-level TLIF), and i-FACTOR® P-15 Peptide Enhanced Bone Graft, an established product approved for anterior cervical discectomy and fusion (ACDF) in use since 2015. Both products incorporate P-15 peptide technology to enhance osteogenic activity and bone formation. Cerapedics emphasizes rigorous clinical evidence and patient outcomes in their marketing and regulatory approach. The company maintains regulatory compliance with FDA approval for spinal fusion applications and conducts clinical trials to demonstrate superiority versus standard autograft solutions. Manufacturing and distribution capabilities support surgeon access across spine surgery centers and hospitals. The company serves orthopedic surgeons, spine specialists, and hospital networks focused on improving fusion outcomes and reducing operative time.